Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Strongbridge Bio Ord (NQ: SBBP)
4.640 USD  -0.030 (-0.64%)
Official Closing Price  /  Updated: 4:00 PM EST, Feb 21, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 115,100
Open 4.630
Bid (Size) 3.900 (1)
Ask (Size) 5.150 (2)
Prev. Close 4.670
Today's Range 4.500 - 4.700
52wk Range 3.820 - 9.250
Shares Outstanding 35,335,026
Dividend Yield N/A
Performance
YTD
+4.50%
+4.50%
1 Month
-1.07%
-1.07%
3 Month
-10.94%
-10.94%
6 Month
-13.27%
-13.27%
1 Year
-31.26%
-31.26%
Top News
More News
Strongbridge Biopharma plc to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call on February 26, 2019
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet... Read More
from GlobeNewswire News Releases
Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada
Strongbridge Used Portion of $145 Million Upfront Cash Payment from Novo Nordisk to Fully Repay Outstanding Debt Read More
from GlobeNewswire News Releases
More News
Read More
Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes — N
from GlobeNewswire News Releases
Strongbridge Biopharma plc Announces Presentation of New Data Comparing the In Vitro Effects of Levoketoconazole, the Active Ingredient in RECORLEV™, and Ketoconazole on Human Cortisol Production
from GlobeNewswire News Releases
Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
from GlobeNewswire News Releases
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
from PR Newswire
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
The Implied Analyst 12-Month Target For SPTM
category ETFs
from ETF Channel
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)
from GlobeNewswire News Releases
Peek Under The Hood: SPTM Has 17% Upside
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.